Chitosan oligosaccharides alleviate cognitive deficits in an amyloid-β1-42-induced rat model of Alzheimer's disease

Int J Biol Macromol. 2016 Feb:83:416-25. doi: 10.1016/j.ijbiomac.2015.11.011. Epub 2015 Nov 18.

Abstract

Aim: The objective of the present study was two-fold: (i) to evaluate the modulating effects of chitosan oligosaccharides (COS) on cognitive deficits and (ii) to explore their underlying molecular mechanisms.

Methods: The Morris water maze and passive avoidance tests were used to determine the neuroprotective effects of COS on Aβ1-42-induced learning and memory impairments. Biochemical methods were then used to assess COS antioxidant activity in hippocampus, including effects on apoptosis (TUNEL assay) and changes in inflammatory mediators (immunohistochemistry).

Results: Orally administered COS at 200, 400, or 800 mg/kg doses were effective at reducing the learning and memory deficits in Aβ1-42-induced rats. These same doses were also able to ameliorate neuronal apoptosis. The neuroprotective effects of COS were closely associated with its ability to inhibit oxidative stress. This was shown with decreasing levels of malondialdehyde, 8-hydroxy-2'-deoxyguanosine and increasing levels of glutathione peroxidase and super oxide dismutase activities. COS were also shown to suppress the inflammatory response and decrease measures of inflammation via a decrease in the release of proinflammatory cytokines (e.g. interleukin-1beta and tumor necrosis factor-alpha).

Conclusion: Taken together, our findings suggest that COS have beneficial effects on the cognitive impairments seen in an Aβ1-42-induced model of Alzheimer's disease via inhibiting oxidative stress and neuroinflammatory responses.

Keywords: Alzheimer's disease; Amyloid-β(1–42); Chitosan oligosaccharides; Neuroinflammation; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Alzheimer Disease / physiopathology*
  • Amyloid beta-Peptides / pharmacology*
  • Animals
  • Apoptosis / drug effects
  • Avoidance Learning / drug effects
  • Chitosan / chemistry*
  • Chitosan / pharmacology*
  • Chitosan / therapeutic use
  • Cognition / drug effects*
  • Disease Models, Animal
  • Glutathione Peroxidase / metabolism
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Hippocampus / physiopathology
  • Male
  • Malondialdehyde / metabolism
  • Maze Learning / drug effects
  • Neurons / drug effects
  • Neurons / metabolism
  • Neurons / pathology
  • Oligosaccharides / chemistry*
  • Oxidative Stress / drug effects
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Superoxide Dismutase / metabolism

Substances

  • Amyloid beta-Peptides
  • Oligosaccharides
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • Malondialdehyde
  • Chitosan
  • Glutathione Peroxidase
  • Superoxide Dismutase